Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

Three months since Suzanne Harrington was prescribed the weight-loss jab Mounjaro, she opens up her diary and reveals all ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.

Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users lose up to 20 per cent body weight. But is it safe? Experts answer.

Sixty-three percent of patients starting on Novo Nordisk's Wegovy or Eli Lilly's Zepbound during the first quarter of 2024 ...

BrightGene Pharmaceutical (Nasdaq: BGNE) unveiled promising mid‑stage results for its investigational treatment BGM0504 at ...

Bimagrumab showed promising fat loss results in a mid-stage trial, but analysts raised concerns about safety and say more ...